The Relationship Between Pain and Depression

Depression and pain frequently co-occur and bidirectionally worsen disability, quality of life, and suicide risk. Shared mechanisms include monoaminergic dysregulation involving serotonin, norepinephrine, and dopamine, hypothalamic–pituitary–adrenal axis perturbation, neuroinflammation, central sensitization with N–methyl–D–aspartate receptor dependent plasticity, and impaired descending inhibitory control. Overlapping genetic architectures, including μ–opioid, galanin, and serotonin receptor variants, further link the conditions. Neuroimaging implicates the insula, thalamus, cingulate, and brainstem circuits that span sensory discriminative and affective motivational dimensions. Psychosocial mediators such as catastrophizing, fear avoidance, low self–efficacy, sleep disturbance, and reduced social reinforcement facilitate the transition from acute to chronic pain and amplify depressive symptoms. Assessment should integrate structured pain phenotyping, including site, quality, intensity, time course, and functional impact, and validated measures of mood and somatic burden. Management is multimodal. Pharmacotherapies with the strongest analgesic signals include tricyclics and serotonin norepinephrine reuptake inhibitors, with adjunctive roles for gabapentinoids, selected anticonvulsants, dopaminergic agents, and ketamine in refractory cases. Psychological interventions, particularly cognitive-behavioral therapy or acceptance and commitment therapy with behavioral activation and sleep strategies, provide moderate effects and potentiate medications. Neuromodulation, including electroconvulsive therapy, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation, benefits selected patients with comorbid depression and pain. This chapter integrates epidemiologic, neurobiologic, and therapeutic evidence to frame a pragmatic biopsychosocial approach.